A shot being developed by AstraZeneca and the University Off Oxford produces a strong immune response in older adults.

That is, according to data from mid stage trials.

They involved 560 healthy volunteers aged from 18 to 70 and over.

The volunteers reported no serious side effects.

Now, researchers say the results suggest that older folk can build robust immunity.

Further trials will aim to confirm the findings and test whether the vaccine can even protect those with underlying health conditions.

A report in The Lancet medical journal says initial results from the late stage tests could be possible in the coming weeks.

The Oxford AstraZeneca offering had Bean seen as among the front runners for an effective treatment, but recent weeks have seen rival drug makers Pfizer by on tech and Moderna edge ahead.